机构：[1]Department of Oncology, Affiliated Hospital of Southwest Medical University, No. 25, Taiping street, Luzhou city, Sichuan, China[2]Department of Oncology, People’s Hospital of Cangxi County, Guangyuan, China[3]Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院[4]Department of Head Neck Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院[5]Institute of Drug Clinical Trial, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院
The aim of this research was to provide data from a single-center study of the treatment of synchronous hypopharyngeal cancer (HPC) and esophageal cancer (EC) with different treatment modalities. A total of 61 patients with synchronous HPC and EC were included in this study. Patients were treated with radiotherapy/chemoradiotherapy (28 cases), surgery (9 cases), palliative radiotherapy and/or chemotherapy (17 cases), or supportive care (7 cases). The median radiotherapy doses for EC and HPC in the radiotherapy/chemoradiotherapy group were 64.5 Gy (range, 0-70) and 70 Gy (range, 60-75.2), respectively. Seven patients in the surgery group received pharyngoesophagectomy with gastric pull-up reconstruction, and two received esophagectomy followed by radiotherapy at the hypopharynx. Cox proportional hazard analysis revealed that the outcome of active treatments, including surgery and radiotherapy/chemoradiotherapy, was better than that of conservative care. In survival analysis, patients in the surgery group tended to have a better 3-year overall survival rate than those in the radiotherapy/chemoradiotherapy group (55.6% vs 30.9%); however, this difference was not statistically different (P = 0.493). The two groups had similar 3-year progression-free survival rates (30.6% and 33.3%, P = 0.420). The current study suggested that radiotherapy/chemoradiotherapy should be considered as an important treatment modality in addition to surgery for synchronous HPC and EC.
基金：
National Science Foundation of ChinaNational Natural Science Foundation of China [81771921]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|4 区医学
小类|3 区生物学4 区肿瘤学4 区核医学
最新[2023]版：
大类|4 区医学
小类|3 区生物学4 区肿瘤学4 区核医学
JCR分区：
出版当年[2019]版：
Q3RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3BIOLOGYQ4ONCOLOGY
最新[2023]版：
Q2BIOLOGYQ3ONCOLOGYQ3RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
第一作者机构：[1]Department of Oncology, Affiliated Hospital of Southwest Medical University, No. 25, Taiping street, Luzhou city, Sichuan, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Oncology, Affiliated Hospital of Southwest Medical University, No. 25, Taiping street, Luzhou city, Sichuan, China[3]Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China[*1]Department of Oncology, Affiliated Hospital of Southwest Medical University, No. 25, Taiping street, Luzhou city, Sichuan, China
推荐引用方式(GB/T 7714)：
Yang Shixuan,Yang Shuang,Liao Wenjun,et al.Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer[J].JOURNAL OF RADIATION RESEARCH.2019,60(5):658-665.doi:10.1093/jrr/rrz042.
APA：
Yang, Shixuan,Yang, Shuang,Liao, Wenjun,Huang, Rui,Li, Baisen...&Zhang, Shichuan.(2019).Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer.JOURNAL OF RADIATION RESEARCH,60,(5)
MLA：
Yang, Shixuan,et al."Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer".JOURNAL OF RADIATION RESEARCH 60..5(2019):658-665
